1. Home
  2. BTCT vs RNTX Comparison

BTCT vs RNTX Comparison

Compare BTCT & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTCT
  • RNTX
  • Stock Information
  • Founded
  • BTCT 2006
  • RNTX 2001
  • Country
  • BTCT Singapore
  • RNTX United States
  • Employees
  • BTCT N/A
  • RNTX N/A
  • Industry
  • BTCT Other Consumer Services
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BTCT Real Estate
  • RNTX Health Care
  • Exchange
  • BTCT Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • BTCT 25.2M
  • RNTX 26.5M
  • IPO Year
  • BTCT N/A
  • RNTX N/A
  • Fundamental
  • Price
  • BTCT $2.42
  • RNTX $1.37
  • Analyst Decision
  • BTCT
  • RNTX Hold
  • Analyst Count
  • BTCT 0
  • RNTX 1
  • Target Price
  • BTCT N/A
  • RNTX N/A
  • AVG Volume (30 Days)
  • BTCT 185.5K
  • RNTX 99.6K
  • Earning Date
  • BTCT 09-16-2025
  • RNTX 08-14-2025
  • Dividend Yield
  • BTCT N/A
  • RNTX N/A
  • EPS Growth
  • BTCT N/A
  • RNTX N/A
  • EPS
  • BTCT N/A
  • RNTX N/A
  • Revenue
  • BTCT $11,675,000.00
  • RNTX N/A
  • Revenue This Year
  • BTCT N/A
  • RNTX N/A
  • Revenue Next Year
  • BTCT $138.54
  • RNTX N/A
  • P/E Ratio
  • BTCT N/A
  • RNTX N/A
  • Revenue Growth
  • BTCT 28.68
  • RNTX N/A
  • 52 Week Low
  • BTCT $1.32
  • RNTX $1.04
  • 52 Week High
  • BTCT $26.58
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • BTCT 37.82
  • RNTX 56.24
  • Support Level
  • BTCT $2.35
  • RNTX $1.06
  • Resistance Level
  • BTCT $2.73
  • RNTX $1.40
  • Average True Range (ATR)
  • BTCT 0.15
  • RNTX 0.13
  • MACD
  • BTCT 0.01
  • RNTX 0.04
  • Stochastic Oscillator
  • BTCT 17.95
  • RNTX 72.29

About BTCT BTC Digital Ltd.

BTC Digital Ltd is a crypto asset technology company based in the U.S. with a focus on bitcoin mining. The company also generates revenue through mining machine resale and rental business operations. Geographically, the financial assets of the company is located in the United States, Singapore, Hong Kong and the PRC.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: